Full video transcriptClick to expand
Auto-generated transcript of @drjenashton's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Let's talk about muscle loss on GLP1 medications.
- 0:03I want to be crystal clear.
- 0:05This is not a reason not to take these medications.
- 0:09It is a known likely side effect of GLP1 medications
- 0:15that up to 40 or even 45% of pounds lost
- 0:19will be from lean muscle mass.
- 0:22This is where it's so important to look beyond
- 0:25the number on the scale and really understand
- 0:28the nutritional impact and the body composition impact
- 0:32of losing a significant portion of weight
- 0:34from lean muscle mass.
- 0:36What rarely gets explained when you hear that headline
- 0:40is that for people with the conditions of obesity
- 0:44and overweight, the skeletal muscle that they have
- 0:48is not healthy, not optimally functioning skeletal muscle.
- 0:52So you can almost think of it as you're losing something
- 0:56that wasn't working well to begin with.
- 0:58For anyone who loses body weight at any weight,
- 1:02if someone loses five pounds,
- 1:04that is not five pounds purely 100% coming from fat tissue.
- 1:10It always has some degree of fat mass and lean mass.
- 1:16So prioritizing protein is key for helping to minimize
- 1:20the excess muscle loss that can occur on these medications
- 1:23and stimulating that muscle in a positive way
- 1:27with resistance training, i.e. lifting weights
- 1:30is critically important.
- 1:31It's not either or it's both.
GLP-1s and muscle loss in menopausal women: what's real
Quick answer
GLP-1 receptor agonists including semaglutide and tirzepatide are associated with lean mass loss alongside fat mass loss, with trial data generally showing 25-39% of total weight loss coming from lean tissue, a figure that can shift higher without adequate protein intake and resistance training. Postmenopausal women face compounded risk due to estrogen-related reductions in muscle protein synthesis, making body composition monitoring and resistance exercise particularly relevant in this population. Current obesity medicine guidance recommends combining GLP-1 therapy with structured resistance training and higher protein intake to help preserve lean mass, though long-term data specific to postmenopausal women on these medications remains limited.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1s and muscle loss in menopausal women: what's real, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1s and muscle loss in menopausal women: what's real should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1s and muscle loss in menopausal women: what's real" from drjenashton. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists including semaglutide and tirzepatide are associated with lean mass loss alongside fat mass loss, with trial data generally showing 25-39% of total weight loss coming from lean tissue, a figure that can shift higher without adequate protein intake and resistance training.
The reason this review is not generic is the source wording and the canonical claim label "glp1 if you are a woman in or past menopause and you are on a glp." In this clip, the useful excerpt is: "Let's talk about muscle loss on GLP1 medications." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists including semaglutide and tirzepatide are associated with lean mass loss alongside fat mass loss, with trial data generally showing 25-39% of total weight loss coming from lean tissue, a figure that can shift higher without adequate protein intake and resistance training.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists including semaglutide and tirzepatide are associated with lean mass loss alongside fat mass loss, with trial data generally showing 25-39% of total weight loss coming from lean tissue, a figure that can shift higher without adequate protein intake and resistance training. Postmenopausal women face compounded risk due to estrogen-related reductions in muscle protein synthesis, making body composition monitoring and resistance exercise particularly relevant in this population. Current obesity medicine guidance recommends combining GLP-1 therapy with structured resistance training and higher protein intake to help preserve lean mass, though long-term data specific to postmenopausal women on these medications remains limited.
- STEP 1 trial data (Wilding et al., 2021) shows roughly 35% of weight lost on semaglutide comes from lean mass, not the 45% ceiling figure Ashton cited, though outcomes vary significantly by diet and exercise habits.
- Obesity is associated with myosteatosis and impaired muscle function, but this does not make lean mass loss on GLP-1s clinically unimportant, especially for older women with elevated sarcopenia risk.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- STEP 1 trial data (Wilding et al., 2021) shows roughly 35% of weight lost on semaglutide comes from lean mass, not the 45% ceiling figure Ashton cited, though outcomes vary significantly by diet and exercise habits.
- Obesity is associated with myosteatosis and impaired muscle function, but this does not make lean mass loss on GLP-1s clinically unimportant, especially for older women with elevated sarcopenia risk.
- A 2024 Nature Medicine study found that combining semaglutide with resistance training preserved significantly more lean mass than medication use alone.
- Most obesity medicine and sports medicine guidelines support protein targets of 1.2 to 1.6 grams per kilogram of body weight daily to help offset lean mass loss during GLP-1-driven caloric restriction.
- Postmenopausal women face compounded muscle loss risk due to declining estrogen levels, which reduces muscle protein synthesis independent of medication use.
- No long-term randomized trials have been conducted specifically in postmenopausal women on GLP-1 medications with body composition as a primary endpoint, making this a genuine evidence gap.
- The number on the scale does not distinguish fat loss from muscle loss. DEXA scanning or bioelectrical impedance analysis gives a more complete picture of what is actually being lost.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drjenashton actually say?
Dr. Jen Ashton made three core claims: that GLP-1 medications cause up to "40 or even 45%" of weight lost to come from lean muscle mass, that the skeletal muscle in people with obesity is already "not healthy, not optimally functioning," and that protein intake plus resistance training can help offset this loss. She was careful to frame muscle loss as a known side effect, not a dealbreaker.
To her credit, she avoided the trap most wellness creators fall into: she didn't say stop the medication. She said understand the tradeoffs and act on them. That's a more honest framing than the average TikTok health take, and the general thrust of her advice, eat protein, lift weights, look beyond the scale, is well-supported. But that 40-45% figure deserves a harder look than she gave it.
Does the science back this up?
Partially. The 40-45% lean mass loss figure is plausible but comes with important asterisks most creators skip. Data from the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide users lost roughly 35% of total weight loss from lean mass. A 2023 analysis in Obesity by Bikou et al. found lean mass losses ranging from 25-39% depending on baseline body composition and diet quality.
The 40-45% range appears in some smaller studies and is often cited without specifying the population, diet conditions, or whether participants were doing any resistance training. None of these trials were designed specifically for postmenopausal women, which is a real gap. The honest answer is that lean mass loss on GLP-1s is real and significant, but "up to 45%" is closer to the ceiling of observed data than the average outcome. Stating it as the expected range overstates the typical risk.
What did they get wrong (or right)?
The claim about skeletal muscle quality in people with obesity deserves scrutiny. Ashton said you can "think of it as losing something that wasn't working well to begin with." This is partially true but oversimplified in a way that could be misleading.
Research does show that obesity is associated with myosteatosis, fat infiltration into muscle tissue, and impaired muscle function (Bhasin et al., 2021, Journal of Clinical Endocrinology and Metabolism). But muscle quantity still matters for metabolic rate, insulin sensitivity, and functional mobility. Framing the loss as losing broken tissue risks minimizing a real concern, particularly for older women already experiencing age-related muscle decline. Sarcopenia risk in postmenopausal women is not trivial. Ashton acknowledged this implicitly by pushing resistance training, but the framing could give some viewers cover to ignore the muscle loss issue entirely.
On protein and resistance training, she is on solid ground. Churchward-Venne et al. (2020, Journal of Physiology) and data from the SURMOUNT trials both support the role of resistance exercise in attenuating lean mass loss during caloric restriction and GLP-1 use.
What should you actually know?
If you are on a GLP-1 and not resistance training, you are leaving a meaningful benefit on the table and possibly accelerating a problem you cannot see on the scale. A 2024 study in Nature Medicine (Ghusn et al.) found that participants who combined semaglutide with structured resistance training preserved significantly more lean mass than those who relied on the medication alone.
For postmenopausal women specifically, the stakes are higher. Estrogen decline already accelerates muscle protein breakdown. Adding GLP-1-driven caloric restriction without a protein and resistance training protocol is a real risk, not a hypothetical one. The target protein intake supported by most sports medicine and obesity medicine guidelines is 1.2 to 1.6 grams per kilogram of body weight daily, which most Americans on a GLP-1-induced appetite reduction are not hitting.
The bottom line: Ashton's core message is directionally correct. The specific numbers she cites are at the upper end of the evidence. And her framing of compromised muscle as less worth preserving should be treated with skepticism, not acceptance.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
drjenashton · TikTok creator
38.5K views on this video
If you are a woman in or past menopause and you are on a GLP-1, or considering one, the conversation you need to be having with yourself is not only about the scale. It's also about muscle. Here is why I keep coming back to this. Women in this stage of life are already losing muscle mass every year, quietly, because of age and the loss of estrogen. That is happening whether or not anyone is on a medication. Add a GLP-1 to that picture, and the potential for accelerated loss of lean tissue become
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about step 1 trial data (wilding et al., 2021) shows roughly?
STEP 1 trial data (Wilding et al., 2021) shows roughly 35% of weight lost on semaglutide comes from lean mass, not the 45% ceiling figure Ashton cited, though outcomes vary significantly by diet and exercise habits.
What does the video say about obesity?
Obesity is associated with myosteatosis and impaired muscle function, but this does not make lean mass loss on GLP-1s clinically unimportant, especially for older women with elevated sarcopenia risk.
What does the video say about a 2024 nature medicine study found?
A 2024 Nature Medicine study found that combining semaglutide with resistance training preserved significantly more lean mass than medication use alone.
What does the video say about most obesity medicine?
Most obesity medicine and sports medicine guidelines support protein targets of 1.2 to 1.6 grams per kilogram of body weight daily to help offset lean mass loss during GLP-1-driven caloric restriction.
What does the video say about postmenopausal women face compounded muscle loss risk due to declining?
Postmenopausal women face compounded muscle loss risk due to declining estrogen levels, which reduces muscle protein synthesis independent of medication use.
What does the video say about no long-term randomized trials have been conducted specifically in postmenopausal?
No long-term randomized trials have been conducted specifically in postmenopausal women on GLP-1 medications with body composition as a primary endpoint, making this a genuine evidence gap.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by drjenashton, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.